Your browser doesn't support javascript.
loading
Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients.
Siriwardana, Amanda N; Hoffman, Anna T; Morton, Rachael L; Smyth, Brendan; Brown, Mark A.
Affiliation
  • Siriwardana AN; Renal and Metabolic Division, The George Institute for Global Health, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Department of Renal Medicine, Royal North Shore Hospital, Sydney, NSW, Australia. Electronic address: asir3810@uni.sydney.edu.au.
  • Hoffman AT; Department of Renal Medicine, St George Hospital, Sydney, NSW, Australia.
  • Morton RL; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Smyth B; Department of Renal Medicine, St George Hospital, Sydney, NSW, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Brown MA; Department of Renal Medicine, St George Hospital, Sydney, NSW, Australia; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Value Health ; 27(4): 469-477, 2024 04.
Article in En | MEDLINE | ID: mdl-38307389
ABSTRACT

OBJECTIVES:

The EQ-5D-5L is a commonly used health-related quality of life instrument for evaluating interventions in patients receiving dialysis; however, the minimal important difference (MID) that constitutes a meaningful treatment effect for this population has not been established. This study aims to estimate the MID for the EQ-5D-5L utility index in dialysis patients.

METHODS:

6-monthly EQ-5D-5L measurements were collected from adult dialysis patients between April 2017 and November 2020 at a renal network in Sydney, Australia. EQ-VAS and Integrated Palliative care Outcome Scale Renal symptom burden scores were collected simultaneously and used as anchors. MID estimates for the EQ-5D-5L utility index were derived using anchor-based and distribution-based methods.

RESULTS:

A total of 352 patients with ≥1 EQ-5D-5L observation were included, constituting 1127 observations. Mean EQ-5D-5L utility index at baseline was 0.719 (SD ± 0.267), and mean EQ-5D-5L utility decreased over time by -0.017 per year (95% CI -0.029 to -0.006, P = .004). Using cross-sectional anchor-based methods, MID estimates ranged from 0.073 to 0.107. Using longitudinal anchor-based methods, MID for improvement and deterioration ranged from 0.046 to 0.079 and -0.111 to -0.048, respectively. Using receiver operating characteristic curves, MID for improvement and deterioration ranged from 0.037 to 0.122 and -0.074 to -0.063, respectively. MID estimates from distribution-based methods were consistent with anchor-based estimates.

CONCLUSIONS:

Anchor-based and distribution-based approaches provided EQ-5D-5L utility index MID estimates ranging from 0.034 to 0.134. These estimates can inform the target difference or "effect size" for clinical trial design among dialysis populations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Renal Dialysis Aspects: Patient_preference Limits: Adult / Humans Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Renal Dialysis Aspects: Patient_preference Limits: Adult / Humans Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2024 Document type: Article Country of publication: